Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
31.35
+0.35 (1.13%)
Sep 22, 2026, 4:00 PM EDT - Market closed
Quince Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Quince Therapeutics stock has a consensus rating of "Buy" and an average price target of $75.17. The average 1-year stock price forecast is 139.78% higher than the current stock price, while the lowest is $65 (+107.34%) and the highest is $98 (+212.60%).
Price Target: $75.17 (+139.78%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Quince Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 3 | 4 | 5 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 6 | 6 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens JMP | Citizens JMP | Buy Upgrades $77 | Buy | Upgrades | $77 | +145.61% | Sep 22, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Initiates $68 | Buy | Initiates | $68 | +116.91% | Aug 20, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $99 → $98 | Buy | Maintains | $99 → $98 | +212.60% | Aug 19, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $80 → $70 | Buy | Reiterates | $80 → $70 | +123.29% | Aug 18, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $82 | Buy | Reiterates | $82 | +161.56% | Aug 17, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.65
from -336.00
EPS Next Year
-4.68
from -3.65
EPS and Forward PE are based on non-GAAP adjusted numbers.